Zeria Pharmaceutical Co., Ltd. Provides Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2022
August 05, 2021 at 12:30 pm IST
Share
Zeria Pharmaceutical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2022. For the first half, the company expects Net sales of JPY 29,000 million, Operating profit of JPY 2,100 million, Ordinary profit of JPY 2,200 million, Profit attributable to owners of parent of JPY 1,500 million and Basic earnings per share of JPY 33.00.
For the full year, the company expects Net sales of JPY 29,000 million, Operating profit of JPY 4,800 million, Ordinary profit of JPY 4,800 million, Profit attributable to owners of parent of JPY 3,300 million and Basic earnings per share of JPY 72.70.
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
ZERIA PHARMACEUTICAL CO., LTD. 
